{"id":"NCT01140347","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","officialTitle":"A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2014-03","completion":"2015-03","firstPosted":"2010-06-09","resultsPosted":"2015-03-26","lastUpdate":"2015-12-28"},"enrollment":565,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Ramucirumab DP (IMC-1121B)","otherNames":["IMC-1121B","LY3009806"]},{"type":"OTHER","name":"BSC","otherNames":[]}],"arms":[{"label":"Ramucirumab DP and BSC","type":"EXPERIMENTAL"},{"label":"Placebo and BSC","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.\n\nApproximately 544 participants, at least 18 years of age, with Child-Pugh score \\< 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.\n\nHypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.\n\nUpon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.\n\nThe treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Randomization to death from any cause (up to 37 months)","effectByArm":[{"arm":"Ramucirumab (IMC-1121B) + BSC","deltaMin":9.17,"sd":null},{"arm":"Placebo + BSC","deltaMin":7.62,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1391"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":17},"locations":{"siteCount":146,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Netherlands","Norway","Philippines","Portugal","Romania","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand"]},"refs":{"pmids":["35247922","34795131","33531690","33188713","32817068","32107609","28950290","28591675","27657674","27549242","26095784"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":277},"commonTop":["Oedema peripheral","Fatigue","Ascites","Decreased appetite","Nausea"]}}